So this looked at patients with ER-positive, HER2-Positive metastatic breast cancer who had received induction chemotherapy with H with or without P. Patients then were randomized to continue ...
Investing.com - Guggenheim has reiterated its Buy rating on AstraZeneca (NASDAQ:AZN) (AZN:LN) with a price target of ...
Clinicians treating patients with estrogen receptor (ER)-positive/HER2-negative metastatic breast cancer are navigating ...
Loose Women star Nadia Sawalha fought back tears as she paid tribute to her 'brave and selfless' friend who sadly passed away ...
The FDA has granted breakthrough therapy designation (BTD) to sevabertinib (Hyrnuo, formerly BAY 2927088) for the first-line ...
At the San Antonio Breast Cancer Symposium (SABCS), investigators outlined the rationale and design of the ERADICATE, a first ...
Daiichi Sankyo plans to splash out some 300 billion yen ($1.9 billion) on Enhertu manufacturing facilities across the globe, ...
The firm is betting that adding the G-quadruplex stabilizer to the ADC will improve outcomes in HER2-low breast cancer patients.
SurvivorNet on MSN
Enhertu significantly cuts recurrence rates for women with high-risk HER2-positive breast cancer — the practice-changing DESTINY-Breast05 trial
For women with a specific type of breast cancer known as HER2-positive (HER2+), any residual (leftover) disease after primary treatment with surgery, chemotherapy, and/or targeted drugs means the risk ...
Senhwa Biosciences, Inc. has reached a major milestone its recent clinical collaboration with BeOne Medicines to explore combination therapy with its marketed PD-1 inhibitor in the field of cold tumor ...
Daiichi Sankyo &AstraZeneca’s Enhertu approved in China as first HER2 directed medicine for patients with HER2 low or HER2 ultralow metastatic breast cancer ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback